Research ArticleArticle
Open Access

Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs

VIVIAN P. BYKERK, POONEH AKHAVAN, GLEN S. HAZLEWOOD, ORIT SCHIEIR, ANNE DOOLEY, BOULOS HARAOUI, MAJED KHRAISHI, SHARON A. LECLERCQ, JEAN LÉGARÉ, DIANE P. MOSHER, JAMES PENCHARZ, JANET E. POPE, JOHN THOMSON, CARTER THORNE, MICHEL ZUMMER and CLAIRE BOMBARDIER
The Journal of Rheumatology August 2012, 39 (8) 1559-1582; DOI: https://doi.org/10.3899/jrheum.110207
  1. Figure 1.
    Figure 1.

    Steps in the systematic review of international guidelines on the pharmacological management of rheumatoid arthritis.

  2. Figure 2.
    Figure 2.

    Algorithm based on the Canadian Rheumatology Association (CRA) recommendations for the pharmacological treatment of rheumatoid arthritis (RA) with traditional and biologic disease-modifying antirheumatic drugs (DMARD). LDA: low disease activity; DMARD: disease-modifying antirheumatic drug; CI: contraindicated; IA: intraarticular; IM: intramuscular; MTX: methotrexate; anti-TNF: tumor necrosis factor inhibitor; ABAT: abatacept; RTX: rituximab; TCZ: tocilizumab.

  3. Figure 3.
    Figure 3.

    Algorithm based on the Canadian Rheumatology Association recommendations for the assessment of patients with rheumatoid arthritis (RA). DMARD: disease-modifying antirheumatic drug; NSAID: nonsteroidal antiinflammatory drugs; MRI: magnetic resonance imaging; CBC: complete blood cell count; RF: rheumatoid factor; anti-CCP: anticyclic citrullinated peptide antibodies; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; CXR: chest radiograph; LTBI: latent tuberculosis infection; HBV/HCV: hepatitis B/C.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Save to my folders

Jump to section